source: internationalization/trunk/TranslationSpreadsheets/WV-DIALOG-0238.txt@ 604

Last change on this file since 604 was 604, checked in by George Lilly, 15 years ago

Internationalization

File size: 13.8 KB
Line 
1English French Notes Complete/Exclude
2 EVIDENCE OF METASTASIS......: Not documented
31402 11. DATE OF FIRST TISSUE DIAGNOSIS
4 12. DISTANCE IN MILLIMETERS TO CLOSEST MARGIN:
51429 PROXIMAL MARGIN..............
61429.1 DISTAL MARGIN................
71417 13. FROZEN SECTION................
81418.3 CHEST WALL...................
9 15. SCOPE OF OPERATIVE MEDIASTINAL LYMPH NODE ASSESSMENT:
101419 HIGHEST MEDIASTINAL (level 1)
111419.1 UPPER PARATRACHEAL (level 2)
121419.2 PREVASCULAR AND RETROTRACHEAL (level 3)
131419.3 LOWER PARATRACHEAL (level 4)
141419.8 PULMONARY LIGAMENT (level 9)
151430 16. HCT (HEMOCRIT) VALUES BEFORE TRANSFUSION..................
161420 17. TOTAL PERI-OPERATIVE BLOOD REPLACEMENT..................
171421 18. PERI-OPERATIVE DEATH..........
18 FIRST COURSE OF TREATMENT - RADIATION THERAPY
19442 19. REGIONAL DOSE (cGy)...........
2056 20. NUMBER OF TREATMENTS TO THIS VOLUME.......................
21363 21. REGIONAL TREATMENT MODALITY...
2251.3 22. RADIATION/SURGERY SEQUENCE....
231422 23. BOOST DOSE (cGy)..............
24127 24. INTENT OF RADIATION TREATMENT.
2575 25. REASON FOR NO RADIATION.......
26 26. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
271424 27. CHEMOTHERAPEUTIC TOXICITY.....
281425 28. CHEMOTHERAPY/SURGERY SEQUENCE.
29 Do not answer data items 15-18.
30 Proceed to data item 19.
31 19. REGIONAL DOSE (cGy)...........:
32 20. NUMBER OF TREATMENTS TO THIS
33 21. REGIONAL TREATMENT MODALITY...:
34 22. RADIATION/SURGERY SEQUENCE....:
35 23. BOOST DOSE (cGy)..............: Not administered
36 24. INTENT OF RADIATION TREATMENT.:
37 25. REASON FOR NO RADIATION.......:
38 Do not answer data items 26-28.
39 Proceed to data item 29.
40 COMPLICATION #1 may not be blank
4181 30. INITIALS OF CASE ABSTRACTOR...
4290 31. DATE CASE WAS ABSTRACTED......
43 2. DURATION OF TOBACCO USE.......:
44 3. PERSONAL HISTORY OF OTHER
45 4. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
46 SHORTNESS OF BREATH..........:
47 PALPABLE LYMPH NODES.........:
48 5. SCREENING FOR HIGH RISK/ASYMPTOMATIC PRESENTATION:
49 CT SCAN......................:
50 6. INITIAL DIAGNOSTIC STUDIES (PRE-THERAPY):
51 HISTORY AND PHYSICAL.........:
52 THOROCOTOMY/OPEN BIOSPY......:
53Print Lung (NSCLC) PCE
54TUMOR EVALUATION
55 7. PULMONARY FUNCTION TESTS:
56 FVC (forced vital capacity)..:
57 FEV (forced expiratory vol)..:
58 8. LIVER FUNCTION TESTS..........:
59 9. RADIOLOGICAL EVALUATION:
60 BONE SCAN....................:
61 VASCULAR INVASION...........:
62 MEDIASTINAL LYMPH NODES.....:
63 SIZE OF DOMINANT TUMOR (mm).:
64 NUMBER OF TUMORS............:
65 EVIDENCE OF METASTASIS......:
66 MRI SCAN OF CHEST............:
67 MRI SCAN OF BRAIN............:
68 X-RAY OF CHEST...............:
6910. PRE-OP LYMPH NODE MAPPING:
70 HIGHEST MEDIASTINAL (level 1):
71 UPPER PARATRACHEAL (level 2):
72 PREVASCULAR AND RETROTRACHEAL
73 LOWER PARATRACHEAL (level 4):
74 PULMONARY LIGAMENT (level 9):
7511. DATE OF FIRST TISSUE DIAGNOSIS:
7612. DISTANCE IN MILLIMETERS TO CLOSEST MARGIN:
7713. FROZEN SECTION................:
78 CHEST WALL...................:
7915. SCOPE OF OPERATIVE MEDIASTINAL LYMPH NODE ASSESSMENT:
8016. HCT (HEMATOCRIT) VALUES BEFORE
8117. TOTAL PERI-OPERATIVE BLOOD
8218. PERI-OPERATIVE DEATH..........:
8319. REGIONAL DOSE (cGy)...........:
8420. NUMBER OF TREATMENTS TO THIS
8521. REGIONAL TREATMENT MODALITY...:
8622. RADIATION/SURGERY SEQUENCE....:
8723. BOOST DOSE (cGy)..............:
8824. INTENT OF RADIATION TREATMENT.:
8925. REASON FOR NO RADIATION.......:
9026. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
9127. CHEMOTHERAPEUTIC TOXICITY.....:
9228. CHEMOTHERAPY/SURGERY SEQUENCE.:
93 COMPLICATION #1..............: 000.00 No complications
9429. INITIALS OF CASE ABSTRACTOR...:
9530. DATE CASE WAS ABSTRACTED......:
96The Class of Case is not 0, 1, 2 or 6.
97The BEHAVIOR is not 2 (melanoma in situ) or 3 (malignant).
989:Print Melanoma PCE
99This primary does not satisfy the Melanoma PCE eligibility criteria:
1001999 Patient Care Evaluation Study of Melanoma
10110. PERSONAL HISTORY OF MELANOMA
10211. PERSONAL HISTORY OF OTHER CANCER
10312. PREGNANCY AT INITIAL DX
10413. EXOGENOUS HORMONES
105 1. INSTITUTION ID NUMBER........:
106 2. ACCESSION NUMBER.............:
107 3. SEQUENCE NUMBER..............:
1089 4. POSTAL CODE AT DIAGNOSIS.....
109 5. DATE OF BIRTH................:
1109 7. SPANISH ORIGIN...............
11118 9. PRIMARY PAYER AT DIAGNOSIS...
1121100 10. PERSONAL HISTORY OF MELANOMA.
1131101 11. PERSONAL HISTORY OF OTHER CA.//
114 1ST SITE CODE...............: C88.8
115 DATE DIAGNOSED..............: 88/8888
116 2ND SITE CODE...............: C88.8
117 1ST SITE CODE...............: C99.9
118 DATE DIAGNOSED..............: 99/9999
119 2ND SITE CODE...............: C99.9
1201102 1ST SITE CODE...............//
1211103 DATE DIAGNOSED..............//
1221104 2ND SITE CODE...............//
1231105 DATE DIAGNOSED..............//
124 PREGNANCY AND HORMONES
125 12. PREGNANCY AT INITIAL DX......: NA, male
126 13. EXOGENOUS HORMONES...........: NA, male patient
1271106 12. PREGNANCY AT INITIAL DX......
1281107 13. EXOGENOUS HORMONES...........
12914. CLASS OF CASE
13015. DATE OF INITIAL DIAGNOSIS
13116. PRIMARY SITE (ICD-O-2)
13217. LOCATION OF DISEASE PRESENTATION
13320. BEHAVIOR CODE(ICD-O-2)
13420. BEHAVIOR CODE (ICD-O-2)
135 14. CLASS OF CASE................:
136 15. DATE OF INITIAL DIAGNOSIS....:
137 16. PRIMARY SITE (ICD-O-2).......:
138 17. LOC OF DISEASE PRESENTATION..: NA, primary site known
1391108 17. LOC OF DISEASE PRESENTATION..
140 20. BEHAVIOR CODE (ICD-O-2)......:
14126 22. DIAGNOSTIC CONFIRMATION......
14223. SIZE OF TUMOR (MELANOMA)
14326. EXTRANODAL EXTENSION
14428. NUMBER OF SATELLITE NODULES
14529. LOCATION OF IN-TRANSIT NODULES
14631. CLARK'S LEVEL OF INVASION
14732. ANGIOLYMPHATIC INVASION
14833. PERINEURAL INVASION
14934. GENERAL SUMMARY STAGE
15035. AJCC CLINICAL STAGE (cTNM)
15137. CLINICALLY AMELANOTIC
15238. AJCC PATHOLOGIC STAGE (pTNM)
15339. STAGED BY
154 TABLE III- EXTENT OF DISEASE AND AJCC STAGE
1551132 23. SIZE OF TUMOR (MELANOMA).....
15633 24. REGIONAL NODES EXAMINED......
15732 25. REGIONAL NODES POSITIVE......
1581110 26. EXTRANODAL EXTENSION.........
159 SATELLITE NODULES OF SKIN OR SUBCUTANEOUS TISSUE
160 28. NUMBER OF SATELLITE NODES....: No satellite nodules
161 28. NUMBER OF SATELLITE NODES....: NA, non-cutaneous melanoma
162 28. NUMBER OF SATELLITE NODES....: Unknown
1631112 28. NUMBER OF SATELLITE NODULES..
1641113 29. LOC OF IN-TRANSIT NODULES....
165 31. CLARK'S LEVEL OF INVASION....: NA, primary site unknown
1661115 31. CLARK'S LEVEL OF INVASION....
167 32. ANGIOLYMPHATIC INVASION......: NA, site unknown or ocular
1681116 32. ANGIOLYMPHATIC INVASION......
169 33. PERINEURAL INVASION..........: NA, site unknown or ocular
1701117 33. PERINEURAL INVASION..........
17135 34. GENERAL SUMMARY STAGE........
172 35. AJCC CLINICAL STAGE (cTNM):
173 36. ULCERATION,,,,,,,,,..........: NA, site unknown or ocular
174 37. CLINICALLY AMELANOTIC........: NA, site unknown or ocular
1751119 37. CLINICALLY AMELANOTIC........
176 38. AJCC PATHOLOGIC STAGE (pTNM):
177 39. STAGED BY:
17819 CLINICAL STAGE...............
17989 PATHOLOGIC STAGE.............
180SENTINEL NODES
181 TABLE IV - FIRST COURSE OF TREATMENT
182346 40. PROTOCOL ELIGIBILITY STATUS...
183 41. PROTOCOL PARTICIPATION........: Not on/NA
184 41. PROTOCOL PARTICIPATION........: Unknown
185560 41. PROTOCOL PARTICIPATION........
186 42. DATE OF FIRST COURSE TREATMENT:
187 43. DATE OF NON CA-DIR SURGERY....:
188 44. NON CANCER-DIRECTED SURGERY...:
1891109 45. TYPE OF BIOPSY................
190 46. DATE OF CANCER-DIR SURGERY....:
191 47. SURGICAL APPROACH.............:
192 48. SURGERY OF PRIMARY SITE.......:
193 49. SURGICAL MARGINS..............:
194 50. DISTANCE FROM TUMOR TO EDGE OF SPECIMEN......................: 998 NA, surgery not performed
1951120 50. DISTANCE FROM TUMOR TO EDGE OF SPECIMEN......................
196 51. SCOPE OF LYMPH NODE SURGERY...:
197 52. NUMBER OF LYMPH NODES REMOVED.:
198 53. SURGERY OF OTHER REGIONAL SITE(S), DISTANT SITE(S),
199 55. SURGICAL CLOSURE..............: NA, surgery not performed
200 55. SURGICAL CLOSURE..............: Unknown
2011121 55. SURGICAL CLOSURE..............
202 56. REASON FOR NO SURGERY.........:
203 57. PRE-OP LYMPHOSCINTIGRAPHY.....: NA, ocular site
2041122 57. PRE-OP LYMPHOSCINTIGRAPHY.....
205 58. SENTINEL NODES DETECTED BY....: NA, not done, ocular site
206 59. SENTINEL NODE BIOPSY..........: NA, not done, ocular site
207 60. SENTINEL NODES EXAMINED.......: NA, not done, ocular site
208 58. SENTINEL NODES DETECTED BY....: Unknown
209 59. SENTINEL NODE BIOPSY..........: Unknown
210 60. SENTINEL NODES EXAMINED.......: Unknown
2111123 58. SENTINEL NODES DETECTED BY....
212943 59. SENTINEL NODE BIOPSY..........
2131124 60. SENTINEL NODES EXAMINED.......
214 61. SENTINEL NODES POSITIVE.......: NA, not done, no exam, ocular site
215 62. HOW WAS SENTINEL NODE PATHOLOGICALLY EXAMINED.......: NA, not done, ocular site
216 61. SENTINEL NODES POSITIVE.......: Unknown
2171125 61. SENTINEL NODES POSITIVE.......
2181126 62. HOW WAS SENTINEL NODE PATHOLOGICALLY EXAMINED.......
219 63. IF SENTINEL NODE(S) POSITIVE:
220 WAS COMPLETE LYMPH NODE DISSECTION PERFORMED..........: NA, not done, no + nodes, ocular site
221 NUMBER OF BASINS DETECTED.....: NA, not done, no + nodes, ocular site
222 NUMBER OF BASINS POSITIVE.....: NA, not done, no basins dissected, ocular
223 NUMBER OF BASINS DETECTED.....: Unknown
224 NUMBER OF BASINS POSITIVE.....: Unknown
2251127 WAS COMPLETE LYMPH NODE DISSECTION PERFORMED..........
226 NUMBER OF BASINS DETECTED....: NA, not done, no + nodes, ocular site
227 NUMBER OF BASINS POSITIVE....: NA, not done, no basins dissected, ocular
228 NUMBER OF BASINS DETECTED....: Unknown
229 NUMBER OF BASINS POSITIVE....: Unknown
2301128 NUMBER OF BASINS DETECTED.....
2311129 NUMBER OF BASINS POSITIVE.....
232 64. DATE RADIATION STARTED........:
233 65. RADIATION THERAPY.............:
234 66. REASON FOR NO RADIATION.......:
235 67. DATE CHEMOTHERAPY STARTED.....:
236 69. INTRAVENOUS THERAPY...........: NA, chemotherapy not administered
237 69. INTRAVENOUS THERAPY...........: Unknown if administered
2381130 69. INTRAVENOUS THERAPY...........
239 70. DATE HORMONE THERAPY STARTED..:
240 71. HORMONE THERAPY...............:
241 72. DATE IMMUNOTHERAPY STARTED....:
242 74. IMMUNOTHERAPEUTIC AGENTS ADMINISTERED:
243 VACCINE THERAPY...............: NA
244 GENE THERAPY..................: NA
245 COLONY STIMULATING FACTORS....: NA
246 OTHER GIVEN, TYPE UNKNOWN.....: NA
247 VACCINE THERAPY...............: Unknown
248 GENE THERAPY..................: Unknown
249 COLONY STIMULATING FACTORS....: Unknown
250 OTHER GIVEN, TYPE UNKNOWN.....: Unknown
251884 VACCINE THERAPY...............
2521131 GENE THERAPY..................
253559 COLONY STIMULATING FACTORS....
254386 OTHER GIVEN, TYPE UNKNOWN.....
255 75. DATE OTHER TREATMENT STARTED..:
256 76. OTHER TREATMENT...............:
25777. DATE OF FIRST RECURRENCE
25878. TYPE OF FIRST RECURRENCE
25979. OTHER TYPE OF FIRST RECURRENCE
26077. TYPE OF FIRST RECURRENCE
26178. DATE OF FIRST RECURRENCE
262 TABLE V - FIRST RECURRENCE
26370 77. DATE OF FIRST RECURRENCE......
26471 78. TYPE OF FIRST RECURRENCE......
26571.4 79. OTHER TYPE OF 1ST RECURRENCE..
26680. DATE OF LAST CONTACT OR DEATH
26781. VITAL STATUS
26882. CANCER STATUS
269 TABLE VI - STATUS AT LAST CONTACT
270 80. DATE OF LAST CONTACT OR DEATH.:
27115 81. VITAL STATUS..................
272 82. CANCER STATUS.................:
27383. COMPLETED BY
27484. REVIEWED BY CANCER COMMITTEE
275 TABLE VII - OTHER INFORMATION
27681 83. COMPLETED BY..................
27782 84. REVIEWED BY CANCER COMMITTEE..
278 1. INSTITUTION ID NUMBER...........:
279 2. ACCESSION NUMBER................:
280 3. SEQUENCE NUMBER.................:
281 4. POSTAL CODE AT DIAGNOSIS........:
282 5. DATE OF BIRTH...................:
283 7. SPANISH ORIGIN..................:
284 9. PRIMARY PAYER AT DIAGNOSIS......:
28510. PERSONAL HISTORY OF MELANOMA....:
28611. PERSONAL HISTORY OF OTHER CA....:
287 1ST SITE CODE..................:
288 DATE DIAGNOSED.................:
289 2ND SITE CODE..................:
290 PREGNANCY AND HORMONES
29112. PREGNANCY AT INITIAL DX.........:
29213. EXOGENOUS HORMONES..............:
29314. CLASS OF CASE...................:
29415. DATE OF INITIAL DIAGNOSIS.......:
29516. PRIMARY SITE (ICD-O-2)..........:
29617. LOC OF DISEASE PRESENTATION.....:
29720. BEHAVIOR CODE (ICD-O-2).........:
29822. DIAGNOSTIC CONFIRMATION.........:
299Print Melanoma PCE
300 1999 Patient Care Evaluation Study of Melanoma
301TABLE III - EXTENT AND STAGE OF DISEASE
30223. SIZE OF TUMOR (mm)..............:
303#################### #################### ####################
304#################### #################### ####################
305#################### #################### ####################
306#################### #################### ####################
307#################### #################### ####################
Note: See TracBrowser for help on using the repository browser.